Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology symbols : Bgne save search
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Published: 2024-04-11 (Crawled : 10:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 0.77%
H: 2.61%
C: 1.96%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -1.55%
H: 0.89%
C: -1.01%
first conference report financial results
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-08 (Crawled : 10:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 0.0%
H: 1.76%
C: -0.62%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.94%
H: 1.12%
C: 0.61%
association cancer research preclinical for meeting
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Published: 2024-03-28 (Crawled : 10:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 0.49%
H: 2.13%
C: 1.64%
SNDX | $20.97 0.82% 0.81% 670K
|
Health Technology
|
| O: 0.48%
H: 4.36%
C: 2.67%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 1.24%
H: 0.24%
C: -0.39%
Zymeworks Announces Participation in Upcoming April 2024 Investor Conferences
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 0.38%
H: 0.67%
C: -2.0%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.49%
H: 1.83%
C: 1.33%
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2024-03-27 (Crawled : 10:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 0.38%
H: 0.67%
C: -2.0%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.49%
H: 1.83%
C: 1.33%
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 10.52%
H: 2.11%
C: -2.49%
brukinsa first collaboration max leukemia
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
Published: 2024-03-09 (Crawled : 20:20) - prnewswire.com
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
CCXI | News | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
| Email alert
Add to watchlist
otezla research
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
fda brukinsa approval treatment
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: -6.93%
H: 9.65%
C: 0.51%
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.12%
H: 0.41%
C: -0.58%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
year financial results
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.1%
H: 0.18%
C: -1.25%
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
pipeline preclinical meeting
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 1.0%
H: 3.14%
C: 1.07%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
association cancer research preclinical meeting
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: -5.91%
brukinsa leukemia
BeiGene to Present at Upcoming Investor Conferences - February 28, 2024
Published: 2024-02-28 (Crawled : 14:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -3.44%
H: 3.23%
C: 2.86%
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
tevimbra fda license application
Zymeworks Announces Participation in Upcoming March 2024 Investor Conferences
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 1.21%
H: 4.95%
C: 3.04%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2024-02-27 (Crawled : 11:00) - globenewswire.com
ZYME | $8.72 -1.47% -1.49% 420K
|
Health Technology
|
| O: 1.21%
H: 4.95%
C: 3.04%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
Published: 2024-02-26 (Crawled : 14:00) - prnewswire.com
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.31%
H: 0.55%
C: -0.66%
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-02-26 (Crawled : 12:00) - biospace.com/
XNCR | $18.19 -1.03% -1.04% 490K
|
Health Technology
|
| O: -0.29%
H: 7.38%
C: 6.02%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
business year financial results
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.